127 related articles for article (PubMed ID: 22139443)
1. Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation.
Sprio AE; Di Scipio F; Ceppi P; Salamone P; Di Carlo F; Scagliotti GV; Papotti M; Ceccarelli A; Berta GN
Cancer Chemother Pharmacol; 2012 Apr; 69(4):983-9. PubMed ID: 22139443
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
3. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner.
Hsueh CT; Kelsen D; Schwartz GK
Clin Cancer Res; 1998 Sep; 4(9):2201-6. PubMed ID: 9748140
[TBL] [Abstract][Full Text] [Related]
4. Differentiation-inducing factor-1 alters canonical Wnt signaling and suppresses alkaline phosphatase expression in osteoblast-like cell lines.
Matsuzaki E; Takahashi-Yanaga F; Miwa Y; Hirata M; Watanabe Y; Sato N; Morimoto S; Hirofuji T; Maeda K; Sasaguri T
J Bone Miner Res; 2006 Aug; 21(8):1307-16. PubMed ID: 16869729
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Subbarayan PR; Lee K; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
[TBL] [Abstract][Full Text] [Related]
6. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
[TBL] [Abstract][Full Text] [Related]
7. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
8. DIF-1 inhibits the Wnt/β-catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines.
Jingushi K; Takahashi-Yanaga F; Yoshihara T; Shiraishi F; Watanabe Y; Hirata M; Morimoto S; Sasaguri T
Biochem Pharmacol; 2012 Jan; 83(1):47-56. PubMed ID: 22005519
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells.
Dolnick R; Wu Q; Angelino NJ; Stephanie LV; Chow KC; Sufrin JR; Dolnick BJ
Cancer Res; 2005 Jul; 65(13):5917-24. PubMed ID: 15994970
[TBL] [Abstract][Full Text] [Related]
10. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
Huang CL; Liu D; Nakano J; Yokomise H; Ueno M; Kadota K; Wada H
Clin Cancer Res; 2007 Dec; 13(23):6938-46. PubMed ID: 18056168
[TBL] [Abstract][Full Text] [Related]
11. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Takagi K; Sowa Y; Cevik OM; Nakanishi R; Sakai T
Int J Oncol; 2008 May; 32(5):1105-10. PubMed ID: 18425338
[TBL] [Abstract][Full Text] [Related]
12. UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA.
Abe S; Kubota T; Otani Y; Furukawa T; Watanabe M; Kumai K; Kitajima M
Jpn J Cancer Res; 2000 Nov; 91(11):1192-8. PubMed ID: 11092986
[TBL] [Abstract][Full Text] [Related]
13. Differentiation-inducing factor-1 suppresses gene expression of cyclin D1 in tumor cells.
Yasmin T; Takahashi-Yanaga F; Mori J; Miwa Y; Hirata M; Watanabe Y; Morimoto S; Sasaguri T
Biochem Biophys Res Commun; 2005 Dec; 338(2):903-9. PubMed ID: 16243295
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
16. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.
Ishida Y; Kawakami K; Tanaka Y; Kanehira E; Omura K; Watanabe G
Anticancer Res; 2002; 22(5):2805-9. PubMed ID: 12530000
[TBL] [Abstract][Full Text] [Related]
17. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
Subbarayan PR; Sarkar M; Nelson G; Benitez E; Singhal S; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
[TBL] [Abstract][Full Text] [Related]
18. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N
Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells.
Tamatani T; Ferdous T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Nagai H; Fujisawa K; Miyamoto Y
Int J Oncol; 2012 Sep; 41(3):1148-56. PubMed ID: 22766915
[TBL] [Abstract][Full Text] [Related]
20. Differentiation-inducing factor-3 inhibits intestinal tumor growth in vitro and in vivo.
Kubokura N; Takahashi-Yanaga F; Arioka M; Yoshihara T; Igawa K; Tomooka K; Morimoto S; Nakatsu Y; Tsuzuki T; Nakabeppu Y; Matsumoto T; Kitazono T; Sasaguri T
J Pharmacol Sci; 2015 Apr; 127(4):446-55. PubMed ID: 25913757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
